澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

醫藥生物股

653.915

-2.167-0.33%

漲家數：12

跌家數：12

平家數：21

市盈率：- -

高：658.393

開：654.909

低：652.025

收：656.082

成交量：3,673.41萬

成交額：1.07億

市值：979.09億

流通市值：944.61億

資料載入中...

總覽新聞資訊

INVION LTD - 從Hanlim藥業和韓國政府研究基金獲得的非稀釋性資金用於食道癌臨牀前項目

IMMUTEP LTD發佈關於Imp761的積極進展：首個針對自身免疫疾病的Lag-3激動劑抗體的I期研究結果

BUZZ-澳大利亞 Dimerix 公司以 48 億美元出售資產，創下 7 個月新高

ACTINOGEN MEDICAL LTD的Xanamia關鍵性2B/3期阿爾茨海默試驗完成247名參與者的隨機分組並開始治療

PROTEOMICS INTERNATIONAL LAB獲得美國專利，用於食管腺癌的Promarkereso診斷測試

MAYNE PHARMA GROUP LTD - 擴建生產設施正式啓用儀式在南澳大利亞薩爾斯堡舉行

PROTEOMICS INTERNATIONAL LAB顯著改變醫生管理DKD的方式 - 研究發表

BUZZ-澳大利亞 Neuren 公司的雷特綜合症療法獲得美國食品藥品管理局（FDA）批准，公司業績飆升

ORTHOCELL LTD - 提交監管申請以在歐盟和英國神經修復市場上商業分銷Remplir

IMRICOR MEDICAL SYSTEMS-CDI - UVA健康獲得機構審查委員會批准，參與公司的Visabl-Afl臨牀試驗

獨立研究在美國血液學會年會上提出，Remestemcel-L在治療SR-Agvhd的臨牀效果上優於Ruxolitinib

Bioxyne - 根據協議，Bls 將生產 THC 糖果產品，供應至哥斯達黎加和巴拿馬的藥用大麻市場

Immutep與Dr. Reddy's達成戰略合作推廣創新腫瘤藥物Eftilagimod Alfa

IMMUTEP LTD - DR. Reddy's 獲得所有北美、歐洲、日本及大中華區外國家的Eftilagimod Alfa獨家權利

IMMUTEP與DR. Reddy’s達成戰略合作，共同推廣創新腫瘤藥物Eftilagimod Alfa

IMMUTEP LTD - 有資格獲得高達3.495億美元的潛在監管開發和商業里程碑付款

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/BK7508/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"醫藥生物股","latestPrice":653.9152,"timestamp":1766465999971,"preClose":656.0824,"halted":0,"volume":36734074,"delay":0,"changeRate":-0.003303,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-2.167175,"latestTime":"12-23 16:00:00 AEDT","open":654.909,"high":658.3928,"low":652.02454,"amount":106893248,"amplitude":0.009707,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1766530800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1766444400000,1766466000000]],"turnoverRate":0.001411,"increases":15,"decrements":12,"flats":17,"marketCap":97909245430.25,"floatMarketCap":94461070867.6875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":658.3928,"amplitude":0.009707,"preClose":656.0824,"low":652.02454,"latestPrice":653.9152,"volume":36734074,"delay":0,"open":654.909,"prevYearClose":936.801,"prevWeekClose":649.741,"prevMonthClose":683.947,"prevQuarterClose":712.826,"fiveDayClose":653.119,"twentyDayClose":668.276,"sixtyDayClose":712.826,"secType":"PLATE","market":"AU","turnoverRate":0.001411,"marketCap":97909245430.25,"floatMarketCap":94461070867.6875,"timestamp":1766465999971,"nameCN":"醫藥生物股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":12,"flat":21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1186267120","title":"INVION LTD - 從Hanlim藥業和韓國政府研究基金獲得的非稀釋性資金用於食道癌臨牀前項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1186267120","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186267120?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 06:39","pubTimestamp":1766443149,"startTime":"0","endTime":"0","summary":"INVION LTD - 从Hanlim药业和韩国政府研究基金获得的非稀释性资金用于食道癌临床前项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7509","BK7096","IVX.AU","BK7508"],"gpt_icon":0},{"id":"1132253135","title":"IMMUTEP LTD發佈關於Imp761的積極進展：首個針對自身免疫疾病的Lag-3激動劑抗體的I期研究結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132253135","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132253135?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 21:02","pubTimestamp":1766408522,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2593103120","title":"BUZZ-澳大利亞 Dimerix 公司以 48 億美元出售資產，創下 7 個月新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2593103120","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593103120?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 12:10","pubTimestamp":1766376617,"startTime":"0","endTime":"0","summary":"12月22日 - ** DimerixDXB.AX股价上涨12.5%至0.63澳元，创七个月来最高水平** 如果涨势得以保持，该股将创下六个月来的最大盘中涨幅** 生物技术公司称美国上市生物技术公司 BioMarin Pharmaceutical BMRN.O将以 48 亿美元收购  公司的美国商业许可合作伙伴 Amicus Therapeutics。** Amicus Therapeutics 是一家生物制药公司，负责向美国市场授权 DXB 的 DMX-200 药物，用于治疗罕见肾病。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL4S3XS07W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","DXB.AU","LU2065170008.USD","BK7067","BK7508","BK4566","IE00B7SZLL34.SGD","FOLD","BK7501","LU2065171311.SGD","IE00B19Z3581.USD","LU2065171402.SGD","LU2065169927.USD","IE00B19Z3B42.SGD","BMRN","BK4139"],"gpt_icon":0},{"id":"1153606662","title":"ACTINOGEN MEDICAL LTD的Xanamia關鍵性2B/3期阿爾茨海默試驗完成247名參與者的隨機分組並開始治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1153606662","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153606662?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 21:02","pubTimestamp":1766062944,"startTime":"0","endTime":"0","summary":"ACTINOGEN MEDICAL LTD的Xanamia关键性2B/3期阿尔茨海默试验完成247名参与者的随机分组并开始治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"1166134718","title":"PROTEOMICS INTERNATIONAL LAB獲得美國專利，用於食管腺癌的Promarkereso診斷測試","url":"https://stock-news.laohu8.com/highlight/detail?id=1166134718","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166134718?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 05:34","pubTimestamp":1765920868,"startTime":"0","endTime":"0","summary":"PROTEOMICS INTERNATIONAL LAB获得了美国专利，用于食管腺癌的Promarkereso诊断测试。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIQ.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"1124731935","title":"MAYNE PHARMA GROUP LTD - 擴建生產設施正式啓用儀式在南澳大利亞薩爾斯堡舉行","url":"https://stock-news.laohu8.com/highlight/detail?id=1124731935","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124731935?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 10:43","pubTimestamp":1765852990,"startTime":"0","endTime":"0","summary":"MAYNE PHARMA GROUP LTD - 扩建生产设施正式启用仪式在南澳大利亚萨尔斯堡举行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"1152204478","title":"PROTEOMICS INTERNATIONAL LAB顯著改變醫生管理DKD的方式 - 研究發表","url":"https://stock-news.laohu8.com/highlight/detail?id=1152204478","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152204478?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 05:47","pubTimestamp":1765835228,"startTime":"0","endTime":"0","summary":"PROTEOMICS INTERNATIONAL LAB显著改变医生管理DKD的方式 - 研究发表","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PIQ.AU","BK7048"],"gpt_icon":0},{"id":"2591984636","title":"BUZZ-澳大利亞 Neuren 公司的雷特綜合症療法獲得美國食品藥品管理局（FDA）批准，公司業績飆升","url":"https://stock-news.laohu8.com/highlight/detail?id=2591984636","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591984636?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 08:42","pubTimestamp":1765759362,"startTime":"0","endTime":"0","summary":"12月15日 - ** Neuren Pharmaceuticals NEU.AX 股价飙升3.8%至19.73澳元，创下自12月5日以来的最大盘中涨幅** 该公司称，  合作伙伴Acadia Pharmaceuticals ACAD.O获得了美国FDA对DAYBUE STIX trofinetide 口服液的批准。DAYBUE STIX 的口服溶液获得美国 FDA 批准** DAYBUE STIX 是一种粉末配方，用于治疗雷特综合症** 公司获得净销售额的特许权使用费** 截至目前，公司股价上涨了 57.6%。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4S3XL01R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK7508","NEU.AU","LU2065171402.SGD","BK7096","LU2065171311.SGD","BK4139","LU2065170008.USD","ACAD"],"gpt_icon":0},{"id":"1129794615","title":"ORTHOCELL LTD - 提交監管申請以在歐盟和英國神經修復市場上商業分銷Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=1129794615","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129794615?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 06:07","pubTimestamp":1765750031,"startTime":"0","endTime":"0","summary":"ORTHOCELL LTD - 提交监管申请以在欧盟和英国神经修复市场上商业分销Remplir","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"1104146213","title":"IMRICOR MEDICAL SYSTEMS-CDI - UVA健康獲得機構審查委員會批准，參與公司的Visabl-Afl臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1104146213","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104146213?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 05:26","pubTimestamp":1765747570,"startTime":"0","endTime":"0","summary":"IMRICOR MEDICAL SYSTEMS-CDI - UVA健康获得机构审查委员会批准，参与公司的Visabl-Afl临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","BK7007","BK7508","IMR.AU"],"gpt_icon":0},{"id":"1100916668","title":"獨立研究在美國血液學會年會上提出，Remestemcel-L在治療SR-Agvhd的臨牀效果上優於Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1100916668","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100916668?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 07:26","pubTimestamp":1765495606,"startTime":"0","endTime":"0","summary":"独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","MSB.AU","BK7501"],"gpt_icon":0},{"id":"1193667877","title":"Bioxyne - 根據協議，Bls 將生產 THC 糖果產品，供應至哥斯達黎加和巴拿馬的藥用大麻市場","url":"https://stock-news.laohu8.com/highlight/detail?id=1193667877","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193667877?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 05:48","pubTimestamp":1765403291,"startTime":"0","endTime":"0","summary":"Bioxyne - 根据协议，Bls 将生产 THC 糖果产品，供应至哥斯达黎加和巴拿马的药用大麻市场","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BXN.AU","BK7508","BK7111"],"gpt_icon":0},{"id":"1173503970","title":"Immutep與Dr. Reddy's達成戰略合作 推廣創新腫瘤藥物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1173503970","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173503970?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199884,"startTime":"0","endTime":"0","summary":"12月8日 - Immutep Ltd宣布，Immutep与Dr. Reddy’s达成了战略合作协议，共同推广一种创新的肿瘤药物Eftilagimod Alfa。根据协议，Immutep将获得2,000万美元的预付款，以及最高可达3.495亿美元的额外资金。此外，Dr. Reddy's将获得在北美、欧洲、日本及大中华区以外所有国家对Eftilagimod Alfa的独家权利。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"1138437616","title":"IMMUTEP LTD - DR. Reddy's 獲得所有北美、歐洲、日本及大中華區外國家的Eftilagimod Alfa獨家權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1138437616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138437616?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:09","pubTimestamp":1765199347,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"1156951078","title":"IMMUTEP與DR. Reddy’s達成戰略合作，共同推廣創新腫瘤藥物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1156951078","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156951078?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199131,"startTime":"0","endTime":"0","summary":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"1192332602","title":"IMMUTEP LTD - 有資格獲得高達3.495億美元的潛在監管開發和商業里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1192332602","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192332602?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 15:30","pubTimestamp":1765179011,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - 有资格获得高达3.495亿美元的潜在监管开发和商业里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}